Udai Kammula is recruiting patients for a PHASE2 clinical trial testing immunotherapy for mesothelioma.
The trial, designated NCT03935893, aims to enroll up to 240 participants at 1 sites, including locations in Pennsylvania.
About the Study
This is a Phase 2 study to evaluate the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with locally advanced, recurrent, or metastatic cancer associated with one of the following cancer types: 1.) gastric/esophagogastric, 2.) colorectal, 3.) pancreatic, 4.) sarcoma, 5.) mesothelioma, 6.) neuroendocrine, 7.) squamous cell cancer, 8.) Merkle cell, 9.) mismatch repair deficient and/or microsatellite unstable cancers, and 10.) patients who have exhausted conventional systemic therapy options by using the objective response rate (ORR).
Treatment Approach
This trial uses checkpoint inhibitor immunotherapy.
Key trial details:
- Phase: PHASE2
- Sponsor: Udai Kammula
- Enrollment target: 240
- Status: RECRUITING
Why This Trial Matters
Study Locations
The trial is recruiting at:
- UPMC Hillman Cancer Center, Pennsylvania
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening